Latest Clinical News

More Risk than Benefit with TSH Suppression in Thyroid Cancer without High Risk of Recurrence (05-21-2015)

For patients undergoing treatment for thyroid cancer who aren’t at high risk of recurrence, therapy to suppress thyrotropin (TSH) may be ineffective as well as risky. These findings were published in the journal Thyroid. Differentiated thyroid cancer... Continue Reading

Xilonix™ Promising as Treatment for Non–Small Cell Lung Cancer (05-20-2015)

The new targeted agent Xilonix™ appears effective in the treatment a non–small cell lung cancer (NSCLC). The biotechnology company XBoitech Inc recently announced clinical trial findings for the drug.[i],[ii] Xilonix is a type of drug known as a true... Continue Reading

Target Therapy Sutent® Promising in Advanced Thyroid Cancer (05-19-2015)

The targeted therapy Sutent® (sunitinib) appears effective in the treatment of patients with advanced differentiated thyroid cancers. The Endocrine Society announced these Phase II trial findings in a press release. Study results were also presented... Continue Reading

Personalized Screening Test for Ovarian Cancer Potentially Game-Changing, says GlobalData (05-18-2015)

   LONDON, UK (GlobalData), 12 May 2015 – The encouraging recent results of a 14-year study by the UK Collaborative Trial of Ovarian Cancer Screening could herald a radical departure from the approach established by other screening tests for... Continue Reading

Reolysin® Receives FDA Designation for Gastric Cancer (05-14-2015)

The U.S. Food and Drug Administration (FDA) has granted an Orphan Drug Designation (ODD) to Reolysin®, an injectable cancer-killing virus, for the treatment of gastric cancer. Oncolytics Biotech® Inc. recently announced the designation in a press release. The... Continue Reading

Statin Drugs Can Delay Prostate Cancer in Patients Receiving Androgen Deprivation Therapy, Study Shows (05-13-2015)

Men who went on cholesterol-lowering statin drugs when they began androgen deprivation therapy for prostate cancer had a longer time in which their disease was under control than did men who didn’t take statins, a clinical trial led by Dana-Farber Cancer... Continue Reading

Regular Screening of Barrett’s Esophagus Patients Improves Rate of Early Cancer Detection (05-12-2015)

Patients with Barrett’s esophagus who undergo regular exams have an improved chance that precancerous changes and esophageal cancer will be detected early. These findings were published in the journal Gut. Barrett’s esophagus is a pre-cancerous condition... Continue Reading

Melanoma Drug T-VEC Receives Recommendation for FDA Approval (05-1-2015)

An advisory panel to the U.S. Food and Drug Administration (FDA) has recommended approval of the investigational drug T-VEC (talimogene laherparepvec) for the treatment of metastatic melanoma. Biopharmaceutical company Amgen recently announced plans to... Continue Reading

Dose-Dense Chemotherapy with Ellence®, Cytoxan®, and Taxol® May Improve Survival in Node-Positive Breast Cancer (04-30-2015)

Patients with early-stage node-positive breast cancer who receive dose-dense adjuvant chemotherapy with Ellence® (epirubicin), Cytoxan® (cyclophosphamide), and Taxol® (paclitaxel) may have improved disease-free survival. These findings were released... Continue Reading

Combination of Avastin®, Taxol®, and Carboplatin Improves Survival in Recurrent Platinum-Sensitive Ovarian Cancer (04-29-2015)

The addition of Avastin® (bevacizumab) to Taxol® (paclitaxel) and carboplatin for the treatment of recurrent platinum-sensitive ovarian cancer appears to improve survival. These findings were presented at the 2015 Annual Meeting on Women’s Cancer,... Continue Reading

EGFR Testing in Advanced Lung Cancer Appears Underutilized (04-28-2015)

The results of a recent survey suggest that nearly a quarter of advanced lung cancer patients fail to receive epidermal growth factor receptor (EGFR) testing before starting treatment. The recent development of drugs that target EGFR has expanded treatment... Continue Reading

Personalized Immunotherapy Delays Recurrence in Ovarian Cancer (04-28-2015)

A new immunotherapy known as Vigil™ may help delay the recurrence of advanced ovarian cancer. These findings were presented at the 2015 Annual Meeting on Women’s Cancer, March 28–31, in Chicago, Illinois. According to the American Cancer Society... Continue Reading

Next Page »